Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma
Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Glioblastoma (GBM) is an aggressive brain tumour with limited treatment options and poor prognosis, largely due to its heterogeneity and the involvement of multiple intracellular signalling pathways that contribute to drug resistance. Standard therapies have not significantly improved patient outcomes over the past two decades. While recent advance...
Alternative Titles
Full title
Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3134571097
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3134571097
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/2024.11.26.625442
How to access this item
https://www.proquest.com/docview/3134571097?pq-origsite=primo&accountid=13902
